https://www.selleckchem.com/pr....oducts/pexidartinib-
For the analytical validation, we achieved 100% sensitivity and specificity for the detection of known mutations in the reference standards. The limit of detection was 1% allelic frequency. Clinical validation showed that the clinical sensitivity and specificity of the assay for detecting EGFR mutation were 83.3% and 100% respectively. In addition, the NGS panel also detected other mutations of uncertain significance in 6 out of 10 patients. This preliminary analysis showed that the custom 15-gene ctDNA NGS panel demonstrat
Like
Comment
Share
